PENYAKIT TB (WHO found that levels of TB resistant to a range of drugs were far higher than expected.)

A new World Health Organisation (WHO) report paints a worrying picture about the drug-resistant strands of tuberculosis (TB).

In a survey of more than 90,000 patients in 81 countries, the WHO found that levels of TB resistant to a range of drugs were far higher than expected.

“What we found in this new report is that we have levels that are unprecedented, which no one would have [expected],” said Dr Mario Raviglione, director of tuberculosis research at the WHO.

“We suspected that this would be possible in some parts of the world, especially the former Soviet Union and some parts of China. [But] we also found that there is MDR-TB – which is multi-drug resistant forms of tuberculosis.”

The WHO says nearly half a million people around the world will become infected with a drug resistant form of TB every year.

Dr Raviglione says drug-resistant TB has been found in 45 countries, but may also be present in other countries as limited data was available from Africa.

“When there is multi-drug resistant TB, it is then an issue of managing the cases that exist in a proper way, which requires a major investment … because these cases have to be treated with expensive drugs for up to two years,” Dr Raviglione said.

“All of this requires essentially two things. That countries that are affected deal with the issue properly. [And] that their governments really put together a TB control program that works, which is not the case in some parts of the world.”

Twenty-two cases of multi-drug resistant TB were diagnosed in Australia in one year – the highest number ever recorded here.

“The problem with multi-drug resistant TB is that it does take much longer to cure. It is much more expensive. People usually have to stay in hospital a long time and there are more side-effects often from the drugs,” said the Northern Territory Health Department’s Dr Vicki Krause, who is also chair of the National Tuberculosis Advisory Committee.

“It [is] certainly a situation aspect of the disease that we want to keep at a very low rate.”

Dr Krause says the WHO report is concerning.

But she says, compared with other countries, Australia is on top of the problem

“We are a wealthy country. We have excellent laboratory facilities, and this is the one area that is very important in this situation of multi-drug resistance. That you need to know what you are dealing with, and that means that you need to have good laboratory facilities,” Dr Krause said.

“But in our very near neighbours, the ability even to show that someone has something in their sputum – which is what they cough up – is a very difficult situation.”

ILMU PENGETAHUAN BERKENAAN LEUKEMIA.

Causes of Leukemia

The exact cause of most types of leukemia is unknown. Many patients do not exhibit any of the known risk factors, which include smoking and other tobacco use, exposure to high doses of radiation or the chemicals benzene or formaldehyde, and chemotherapy used to treat other cancers. Leukemia is not an inherited disease, but there may be a genetic link. Depending on the type of leukemia, close relatives of a person with leukemia may be up to four times as likely to develop leukemia as a person with no affected relatives. Down syndrome and certain types of blood disorders also increase the risk of developing the disease.

 

 

Symptoms and Diagnosis of Leukemia

As affected cells increase, they begin to crowd out normal cells and disable them, causing symptoms such as frequent infections, poor healing of small cuts or sores, and anemia. The leukemia cells may also collect in certain parts of the body, causing pain and swelling. Other common symptoms include: fevers and night sweats, weakness and fatigue, headaches, bruising of the skin and bleeding from the gums or rectum, joint pain, swelling in the abdomen from an enlarged spleen, swollen lymph nodes in the armpit, neck, or groin, and decreased appetite or weight loss.

If you or a relative has leukemia symptoms, a personal and family medical history will be taken, and a blood sample sent to the lab for testing. If your blood tests are abnormal, a test of bone marrow cells will be taken to confirm the diagnosis. A spinal tap (lumbar puncture) may also be ordered to determine whether leukemia cells are present in the brain or cerebrospinal fluid.

 

Treatment of Leukemia

Treatment depends on the type of leukemia and the stage of progression, but commonly includes one or more bone marrow transplants, radiation, and chemotherapy. Our understanding and ability to treat leukemia has come a long way in recent decades. In 1960, the 5-year survival rate for all types of leukemia was about 14%. Now it is about 50%. The highest survival rates occur in children suffering from ALL.

 

 SILA HUBUNGI SAYA KALAU ANDA INGIN MENCUBA TRANFER FACTOR 4LIFE.

IBRAHIM MELAKA 0163581794/0163153132

KAJIAN SAINS TENTANG BARAH DAN TRANFER FACTOR.

SILA BACA UNTUK ILMU.

 

 

CANCER RESEARCH – CHEMOTHERAPY AND REAL THERAPIES

 

“The medical establishment works closely with the drug multinationals whose main objective is profits, and whose worst nightmare would be an epidemic of good health. Lots of drugs MUST be sold. In order to achieve this, anything goes: lies, fraud, and kickbacks. Doctors are the principal salespeople of the drug companies. They are rewarded with research grants, gifts, and lavish perks. The principal buyers are the public – from infants to the elderly – who MUST be thoroughly medicated and vaccinated…at any cost!”

 

“Why do the authorities forbid alternative medicine? Because they are serving the industry, and the industry cannot make money with herbs, vitamins, and homeopathy. They cannot patent natural remedies. That is why they push synthetics. They control medicine, and that is why they are able to tell medical schools what they can and cannot teach.” Guylaine Lanctot, M.D

 

 

Effect of Transfer Factor

Advanced Formulas

Containing E-XF Blends on

Natural Killer (NK) Cell

Activity

A 4Life Summary of an Independent NK

Cell Study Report by Calvin W.

McCausland, Ph.D. and Emma Oganova

M.D., Ph.D.

 

 

Summary Objective:

To determine the extent to which Transfer Factor E-XF blends and 4Life Transfer Factor Plus Advanced Formula increases Natural Killer (NK) cell activity above

baseline.

 

Study Design:

 The blinded

cytotoxicity study was designed by Dr.E. Oganova and Dr. C. McCausland.

The independent testing of the coded samples was done under the direction

of Academician Anatoly Vorobiev, M.D., Russian Academy of Medical

Sciences (RAMS) and the experimental work was conducted by.

Dr. M.V. Kisielevsky, Dr. E.O. Khalturina, at the Russian Cancer

Research Center, RAMS

 

 

 

 

 

 

Methods: Blood was obtained from RORC donor station. A standard

for 24 or 48 hours. Next 30 thousand K-562 tumor cells (erythroblastic human leukemia) were introduced into the wells. (Thus, the ratio of effector and target cells was 2:1. Each sample was tested in triplicate). The preparations containing both the effector (NK cells) and target cells (K562 cancer cells) along with control wells were again incubated for 18-24 hours under the same incubator conditions. AnMTT (dye) solution was used to spectro-photometricly determine the number of viable cells remaining in each well. The cytotoxic index (CI) expressed in % is reported for each

sample.

 

Results: Each of the samples significantly increased NK cellactivity. The Transfer Factor E-XF Blend (Advanced Formula) resulted in method of density gradient was used to isolate mononuclear cells [NK Cells].The isolated cells, 60 thousand cells

per well, in 100 ml of culture medium,were introduced into each well ofCostar 96 well plates. Then, portions of coded test samples [Transfer Factor

E-XF blends of selected ratios, 4Life Transfer Factor Plus E-XF blend and

others samples] were introduced into the wells at predetermined

concentrations (wt/vol.). An Interleukin-2 (IL-2) standard was used to compare effectiveness. The preparations were incubated in a COzincubator with a 5% C02 atmosphere, 100% humidity and 37° C greater NK cell activation (283%) than

the Transfer Factor XF (204%). 4Life Transfer Factor Plus Advanced

Formula increased NK cell activity by 437%. The drug IL-2 increased NK

cell active by 389%. In the study activation by 4Life Transfer Factor

Advanced Formula, 4Life Transfer Factor Plus Advanced Formula and IL-

2 resulted in a kill rate of K562 cancer cells of 69%, 97% and 88%

respectively with the 48 hour incubation period giving the greatest NK cell activation.

 

 

Discussion

 

As previously reported in earlier publications two 4Life products, 4Life

Transfer Factor Classic and 4Life Transfer Factor Plus, have been

shown to significantly improve NK cell activation, 103% and 248%

respectively. When the transfer factors from patented egg technology

are combined with bovine transfer factors there is a synergistic

activation ofNK cell activity. The improved formulas, 4Life Transfer

Factor and 4Life Transfer Factor Plus Advanced Formulas improve NK

cell activation by 283% and 437% respectively.

4Life researchers and scientists in developing the Advanced Formulas

were confident that the colostrum derived transfer factors when

combined with the egg derived transfer factors (E-XF blends) would

enhance the activity and benefit of the products, but we too were taken

by surprise by the magnitude of the increase. Further research needs to

be done to better understand why this synergism occurs. We are

confident these results will translate into increased benefits to

consumers and increased clinical effect in future studies.

This study was conducted under the direction of Dr. Anatoli Vorobiev

by his colleagues of the Russian Academy of Medical Science. Using

established methods ofcytotoxicity testing, NK cells from humans were

combined with cancer cells and divided into groups of transfer factors

activated NK cells and groups ofunactivated NK cells. The objective

was to find the bovine and egg transfer factor blend(s) (E-XF blends)

that express the greatest NK cell activation. The results enable us to

identify the most potent combination that will provide the greatest

health benefits.

In the control series of the experiments for all of the transfer factor

samples tested there was no direct cytotoxic effect on tumor cells at

any of the concentrations tested. When in the absence of the immune

NK cells the transfer factors are combined directly with the cancer cells

there is no cytotoxic effect on the tumor cells.

Results of this study clearly demonstrated that 4Life Transfer Factor

Advanced Formula and 4Life Transfer Factor Plus Advanced Formula

boosts NK cell activity. The independent research scientists who

conducted this study found the results interesting and so exceptional as

to request further information on the identity of 4Life samples so that

results could be published in professional journals. Statements from

researchers included the following:

“The 4Life sample activated NK cell activity more than the Interleukin-

2 (IL-2) drug used as the standard. Here, we now refer to your sample

as the Golden Interleukin,” stated Dr. Kisielevsky, Russian Academy of

Medical Sciences.

We strongly believe that these results are certain to be reflected in

improved human health resulting from significantly improved immune

response. It is our hope that people everywhere will find that 4Life

Transfer Factor Advanced Formula and 4Life Transfer Factor Plus

Advanced Formula will provide safe broad-spectrum immune support

that is unmatched in any other health supplement today.

 

Darryl See, M.D.

 

Speaking at Convention 2001, Dr. Darryl See, a research scientist who has published over 30 peerreviewed journal articles on chronic viral illnesses and immunological disorders, addressed the audience with come incredibly powerful information regarding Transfer Factor. With a medical degree from the University of California at Irvin and a board certification in both Internal Medicine and Infectious Disease, Dr, See’s studies on Transfer Factor add a vast array of credibility to the

unprecedented impact of this exclusive product.

Dr. See conducted the independent in vitro study that tested hundreds of natural products for their

ability to raise natural killer cell activity, including Transfer Factor and Transfer Factor Plus. Natural killer cells work on the front-line of our immune system, destroying harmful cells through direct contact.

As a result of that study, Dr. See concluded that 4Life Transfer Factor and Transfer Factor Plus far outperformed the competition. Transfer Factor raised Natural Killer (NK) Cell Activity by 102 percent and Transfer Factor Plus raised activity by 248 percent.

 

Recently, Dr. See conducted another study, this time in late stage cancer patients with a regime that included Transfer Factor Plus. He presented the results of this study at the 4Life National Convention. Dr. See again tested NK cell function, as well as the Tumor Necrosis Factor (TNF) in patients. Tumor Necrosis Factor alpha is a cytokine produced primarily by monocytes and macrophages. Also, It is found in synovial cells. It is a substance that has antitumor effects.

 

INCREASED TUMOR NECROSIS FACTOR ALPHA AND NK CELL FUNCTION

USING AN INTEGRATIVE APPROACH IN LATE STAGE CANCERS

PATIENT DEMOGRAPHICS PATIENT REGIME INCLUDED RESULTS AFTER SIX MONTHS

 

Twenty patients

Average age: 49.3

All stage 4 cancers

12 males, 8 females

Prognosis from physician: 3.7 months to live

 

Transfer Factor Plus, Beta Glucans, soy extract, digestive enzymes, vegetarian,

low-sugar diet, hyperthermia and more. Average Tumor Necrosis Factor alpha

(TNF) increased from 12.4 to 1287.5 Average increase in NK cell function:

6.4 to 27.6

 

Sixteen out of the 20 patients studied are in remission, either improving or in stable condition. Dr. See stated that Transfer Factor Plus was an essential part of the regimen.

 When they removed it, the patients’ progress began to slow down. Commenting about the Transfer Factor Plus,

Dr. See said, ”Nothing has ever come close to TF Plus in efficacy …I think everyone in the world should be on this product.”Note: These results are from Dr. See’s independent study. These statements have not been evaluated by the FDA.

These products are not intended to diagnose, treat, cure or prevent any disease.

Reference:

http://health.excite.com/content/article/2946.428

Darryl See, M.D. – Keynote Speaker

www.4-life.com

 

 

BERMINAT UNTUK MENCUBA?? HUBUNGI SAYA DI 0163581794/0163153132 IBRAHIM

ATAU help_linemy@hotmail.com

blog ilmu saya http://helplineenterprise.wordpress.com

Leukemia dan jenis-jenisnya

sila baca untuk ilmu anda.

nLEUKEMIA

LEUKEMIA

           

            Leukemia is cancer of the white blood cells. The bone marrow produces abnormal white blood cells that do not function properly and eventually crowd out normal white blood cells, red blood cells (erythrocytes), and platelets.

There are four major types of leukemia, depending on the type of white blood cell affected and the speed of progression. Blood cells in the bone marrow form from two major groups of stem cells: the myeloid stem cell line and the lymphoid stem cell line. Myeloid stem cells develop into red blood cells, platelets, and certain kinds of white blood cells (granulocytes or monocytes). The lymphoid stem cell line develops into a kind of white blood cell called lymphocytes. Both stem cell lines can be affected by leukemia, and both occur in both acute and chronic forms. Acute leukemia progresses rapidly; chronic more slowly.

 

The four types are:

 

1)Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in children, but it can also affect adults.

2) Acute myelogenous leukemia (AML) is the most common form of leukemia and can affect both children and adults.

 3)Chronic lymphocytic leukemia (CLL) primarily affects people older than 55 years of age, and rarely affects children.

 4) Chronic myelogenous leukemia (CML) affects primarily adults. Unlike CLL, CML eventually but invariably converts to the more rapidly progressing acute form if untreated